NASDAQ:ACET Adicet Bio (ACET) Stock Price, News & Analysis → Here’s how to start a “Weekend Side Hustle” from your sofa (From DTI) (Ad) Free ACET Stock Alerts $2.00 +0.05 (+2.56%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$1.96▼$2.0550-Day Range$1.95▼$3.0052-Week Range$1.10▼$7.50Volume324,300 shsAverage Volume1.56 million shsMarket Capitalization$164.34 millionP/E RatioN/ADividend YieldN/APrice Target$12.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Adicet Bio alerts: Email Address Adicet Bio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.63 Rating ScoreUpside/Downside541.7% Upside$12.83 Price TargetShort InterestBearish9.36% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.02Based on 2 Articles This WeekInsider TradingAcquiring Shares$7.50 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.72) to ($1.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.87 out of 5 starsMedical Sector385th out of 909 stocksPharmaceutical Preparations Industry169th out of 422 stocks 3.3 Analyst's Opinion Consensus RatingAdicet Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageAdicet Bio has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.36% of the outstanding shares of Adicet Bio have been sold short.Short Interest Ratio / Days to CoverAdicet Bio has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Adicet Bio has recently increased by 32.36%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdicet Bio does not currently pay a dividend.Dividend GrowthAdicet Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACET. Previous Next 3.3 News and Social Media Coverage News SentimentAdicet Bio has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Adicet Bio this week, compared to 1 article on an average week.Search Interest18 people have searched for ACET on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Adicet Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -64% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adicet Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,500,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders29.50% of the stock of Adicet Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.89% of the stock of Adicet Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Adicet Bio are expected to decrease in the coming year, from ($1.72) to ($1.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adicet Bio is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adicet Bio is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdicet Bio has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Adicet Bio Stock (NASDAQ:ACET)Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.Read More ACET Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACET Stock News HeadlinesApril 22, 2024 | businesswire.comAdicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual MeetingApril 22, 2024 | americanbankingnews.comAdicet Bio, Inc. (NASDAQ:ACET) Given Consensus Rating of "Moderate Buy" by AnalystsApril 23, 2024 | Wealthpin Pro (Ad)One trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? April 14, 2024 | americanbankingnews.comAdicet Bio, Inc. (NASDAQ:ACET) Short Interest UpdateApril 10, 2024 | seekingalpha.comACET Adicet Bio, Inc.April 8, 2024 | businesswire.comAdicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual ConferenceMarch 28, 2024 | businesswire.comAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)March 28, 2024 | investorplace.comThe Penny Stock A-List: 7 High-Profile Companies on the Verge of GreatnessApril 23, 2024 | Wealthpin Pro (Ad)One trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? March 21, 2024 | finance.yahoo.comAdicet Bio Inc (ACET) Reports Q4 and Full Year 2023 Financial ResultsMarch 21, 2024 | finance.yahoo.comAre Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 41%?March 21, 2024 | markets.businessinsider.comAdicet Bio’s Promising Drug Pipeline and Buy Rating JustificationMarch 20, 2024 | markets.businessinsider.comBuy Recommendation for Adicet Bio Amid Promising Autoimmune and Cancer Therapy DevelopmentsMarch 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Adicet Bio Amid Promising CAR T-Cell Therapies and Strong Financial FootingMarch 20, 2024 | markets.businessinsider.comJMP Securities Keeps Their Hold Rating on Adicet Bio (ACET)March 19, 2024 | investorplace.comACET Stock Earnings: Adicet Bio Meets EPS for Q4 2023March 19, 2024 | benzinga.comAdicet Bio: Q4 Earnings InsightsMarch 19, 2024 | markets.businessinsider.comAdicet Bio, Inc Q4 loss drops in line with estimatesMarch 19, 2024 | businesswire.comAdicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company ProgressMarch 11, 2024 | businesswire.comAdicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceMarch 5, 2024 | investorplace.com3 High-Risk Stocks That Could Pay Off in the MillionsFebruary 29, 2024 | businesswire.comAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)February 27, 2024 | investorplace.com7 Top-Tier Penny Stocks for a Smart BetFebruary 25, 2024 | investorplace.com7 Biotech Penny Stocks on the Verge of Clinical Trial VictoryFebruary 19, 2024 | finance.yahoo.comACET Apr 2024 7.500 callFebruary 13, 2024 | msn.comJones upgrades Adicet to buy, cites upcoming catalystsFebruary 5, 2024 | finance.yahoo.comAdicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceSee More Headlines Receive ACET Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/19/2024Today4/22/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryTrading Companies & Distributors Current SymbolNASDAQ:ACET CUSIP00444610 CIK2034 Webwww.aceto.com Phone(650) 503-9095FaxN/AEmployees143Year FoundedN/APrice Target and Rating Average Stock Price Target$12.83 High Stock Price Target$27.00 Low Stock Price Target$5.00 Potential Upside/Downside+541.7%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-142,660,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-56.63% Return on Assets-48.16% Debt Debt-to-Equity RatioN/A Current Ratio8.41 Quick Ratio8.41 Sales & Book Value Annual Sales$24.99 million Price / Sales6.58 Cash FlowN/A Price / Cash FlowN/A Book Value$2.43 per share Price / Book0.82Miscellaneous Outstanding Shares82,170,000Free Float57,930,000Market Cap$164.34 million OptionableOptionable Beta1.88 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Chen Schor BA (Age 52)CPA, M.B.A., CEO, President & Director Comp: $899.58kDr. Aya Jakobovits Ph.D. (Age 68)Founder & Independent Director Comp: $40kDr. Blake Aftab Ph.D. (Age 43)Senior VP & Chief Scientific Officer Comp: $675.04kDr. Francesco Galimi M.D. (Age 56)Ph.D., Chief Medical Officer & Senior VP Comp: $680.37kMr. Brian Nicholas Harvey (Age 63)Chief Financial Officer Comp: $596.79kDr. Donald Healey Ph.D. (Age 62)Chief Technology Officer Ms. Amy LockeChief Human Resource OfficerDr. Nancy L. Boman M.D.Ph.D., Senior VP & Chief Regulatory OfficerMore ExecutivesKey CompetitorsVeruNASDAQ:VERUTrevi TherapeuticsNASDAQ:TRVIInventivaNASDAQ:IVAGossamer BioNASDAQ:GOSSGreenwich LifeSciencesNASDAQ:GLSIView All CompetitorsInsiders & InstitutionsRTW Investments LPSold 106,841 shares on 2/14/2024Ownership: 5.893%Panagora Asset Management Inc.Bought 51,746 shares on 2/8/2024Ownership: 0.074%Orbimed Advisors LlcBought 3,125,000 shares on 1/25/2024Total: $7.50 M ($2.40/share)Chen SchorBought 5,500 shares on 10/2/2023Total: $7,315.00 ($1.33/share)Chen SchorBought 5,500 shares on 9/28/2023Total: $7,810.00 ($1.42/share)View All Insider TransactionsView All Institutional Transactions ACET Stock Analysis - Frequently Asked Questions Should I buy or sell Adicet Bio stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adicet Bio in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ACET shares. View ACET analyst ratings or view top-rated stocks. What is Adicet Bio's stock price target for 2024? 8 brokerages have issued twelve-month target prices for Adicet Bio's stock. Their ACET share price targets range from $5.00 to $27.00. On average, they anticipate the company's stock price to reach $12.83 in the next year. This suggests a possible upside of 541.7% from the stock's current price. View analysts price targets for ACET or view top-rated stocks among Wall Street analysts. How have ACET shares performed in 2024? Adicet Bio's stock was trading at $1.89 on January 1st, 2024. Since then, ACET stock has increased by 5.8% and is now trading at $2.00. View the best growth stocks for 2024 here. Are investors shorting Adicet Bio? Adicet Bio saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 7,690,000 shares, an increase of 32.4% from the March 15th total of 5,810,000 shares. Based on an average daily trading volume, of 1,690,000 shares, the days-to-cover ratio is presently 4.6 days. View Adicet Bio's Short Interest. When is Adicet Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ACET earnings forecast. How were Adicet Bio's earnings last quarter? Adicet Bio, Inc. (NASDAQ:ACET) released its earnings results on Tuesday, March, 19th. The company reported ($0.69) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.03. What ETFs hold Adicet Bio's stock? ETFs with the largest weight of Adicet Bio (NASDAQ:ACET) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA). What other stocks do shareholders of Adicet Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adicet Bio investors own include FluoroPharma Medical (FPMI), Twitter (TWTR), QUALCOMM (QCOM), Extreme Networks (EXTR), General Electric (GE), Altria Group (MO), Sirius XM (SIRI) and Adobe (ADBE). How do I buy shares of Adicet Bio? Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACET) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adicet Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.